Christopher R. D’Angelo, MD, discusses the BTK inhibitors and their role in primary central nervous system lymphoma.
Christopher R. D’Angelo, MD
Advertisement
Articles by Christopher R. D’Angelo, MD
Christopher R. D’Angelo, MD, discusses emerging therapies in diffuse large B-cell lymphoma.
Christopher R. D’Angelo, MD, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma.
Christopher R. D’Angelo, MD, discusses the potential drawbacks of 5-drug combinations in B-cell lymphoma.
Christopher R. D’Angelo, MD, discusses novel therapeutics under investigation in patients with diffuse large B-cell lymphoma.
Christopher R. D’Angelo, MD, discusses sequencing therapies for patients with lymphoma.
Christopher R. D’Angelo, MD, discusses advances made with CAR T-cell therapy in lymphoma.
Advertisement
Latest Updated Articles
Dr D’Angelo on the Role BTK Inhibitors Play in PCNSLMarch 31st 2026
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Surgeons, Medical Oncologists, and Radiation Oncologists Debate Current Thresholds for Systemic Therapy in EGFR-Mutated NSCLC
5